Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 526-533

  Duan, Lei ^a   Wu, Anna H ^b   Sullivan Halley, Jane ^a   Bernstein, Leslie ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; ANTACIDS; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; LOS ANGELES; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; SELF MEDICATION; STOMACH NEOPLASMS;

EID: 60549090597     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0764     Document Type: Article

References (35)

1. Bochner F, Rossi S. Australian Medicines Handbook 2005. Adelaide: Pharmaceutical Society of Australia; 2005.
2. Chong E, Ensom MHH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003;23:460-71.
3. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
4. Bernstein L. What are the epidemiologic similarities and differences between carcinomas arising in Barrett's mucosa and in the gastric cardia? In: Guili RGJ, Jamieson GG, Scarpignato C, editors. Barrett's Esophagus; Columnar Lined Esophagus. Montrouge. France: John-Libbey Eurotext Ltd; 2003. p. 702-10.
5. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF, Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-7.
6. Colin-Jones DG, Langman MJ, Lawson DH, Logan RF, Paterson KR, Vessey MP. Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus. Q J Med 1991;78:13-9.
7. Farrow DC, Vaughan TL, Sweeney C, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000;11:231-8.
8. Johnson AG, Jick SS, Perera DR, Jick H. Histamine-2 receptor antagonists and gastric cancer. Epidemiology 1996;7:434-6.
9. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
10. Moller H, Lindvig K, Klefter R, Mosbech J, Moller Jensen O. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989; 30:1558-62.
11. Moller H, Nissen A, Mosbech J. Use of cimetidine and other peptic ulcerdrugs inDenmark1977-1990withanalysisoftheriskofgastric cancer among cimetidine users. Gut 1992;33:1166-9.
12. Rodriguez GLA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006;55:1538-44.
13. Beresford J, Colin-Jones DG, Flind AC, et al. Postmarketing surveillance of the safety of cimetidine: 15-year mortality report. Pharmacoepidemiol Drug Saf 1998;7:319-22.
14. La Vecchia C, Negri E, D Avanzo B, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet 1990;336:355-7.
15. Suleiman UL, Harrison M, Britton A, McPherson K, Bates T. H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. Eur J Cancer Prev 2000;9: 185-91.
16. Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003;98:940-8.
17. Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 2008;17:126-34.
18. Wu AH, Crabtree JE, Bernstein L, et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 2003;103:815-21.
19. Wu AH, Tseng CC, Hankin J, Bernstein L. Fiber intake and risk of adenocarcinomas of the esophagus and stomach. Cancer Causes Control 2007;18:713-22.
20. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 2001;12:721-32.
21. Wu YL, Fu SL, Zhang YP, Qiao MM, Chen Y. Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts. Biomed Pharmacother 2005;59 Suppl 2:S289-92.
22. Neumann CS, Cooper BT. 24 hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus. Gut 1994;35: 1352-5.
23. Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987;28:1484-8.
24. Attwood SE, Smyrk TC, DeMeester TR, Mirvish SS, Stein HJ, Hinder RA. Duodenoesophageal reflux and the development of esophageal adenocarcinoma in rats. Surgery 1992;111:503-10.
25. Fein M, Peters JH, Chandrasoma P, et al. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen. J Gastrointest Surg 1998;2:260-8.
26. Ireland AP, Peters JH, Smyrk TC, et al. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann Surg 1996;224:358-70;discussion370-1.
27. Todd JA, de Caestecker J, Jankowski J. Gastro-esophageal reflux disease and bile acids. J Pediatr Gastroenterol Nutr 2003;36:172-4.
28. Marshall RE, Anggiansah A, Owen WA, Owen WJ. The temporal relationship between oesophageal bile reflux and pH in gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 1998;10: 385-92.
29. Chandrasoma PT, Demeester TR. GERD Reflux to Esophageal Adenocarcinoma. Amsterdam: Academic Press; 2006.
30. Fordtran JS, Collyns JA. Antacid pharmacology in duodenal ulcer. Effect of antacids on postcibal gastric acidity and peptic activity. NEngl JMed 1966;274:921-7.
31. Fordtran JS, Morawski SG, Richardson CT. In vivo and in vitro evaluation of liquid antacids. N Engl J Med 1973;288:923-8.
32. Engelhardt D, Karl R, Kolb HJ, et al. Comparison between cimetidine-pirenzepine and antacids for the prevention of stress hemorrhage in intensive care patients. A controlled clinical study on 125 patients. Dtsch Med Wochenschr 1985;110:908-14.
33. Stamp DH. Bile acids aided by acid suppression therapy may be associated with the development of esophageal cancers in westernized societies. Med Hypotheses 2006;66:154-7.
34. Stein HJ, Kauer WK, Feussner H, Siewert JR. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg 1998;2:333-41.
35. H. pylori and Peptic Ulcer. Department of Health and Human Services. NIH Web site. Available from: http://digestive.niddk.nih.gov/ddiseases/pubs/hpylori/ .Accessed July 29, 2008.